Jiangsu Jibeier Pharmaceutical Co., Ltd.

Shanghai Stock Exchange 688566.SS

Jiangsu Jibeier Pharmaceutical Co., Ltd. Revenue for the year ending December 31, 2023: USD 121.26 M

Jiangsu Jibeier Pharmaceutical Co., Ltd. Revenue is USD 121.26 M for the year ending December 31, 2023, a 27.81% change year over year. Revenue is the total amount of money generated from the sales of goods or services by a company during a specific period.
  • Jiangsu Jibeier Pharmaceutical Co., Ltd. Revenue for the year ending December 31, 2022 was USD 94.88 M, a 18.28% change year over year.
  • Jiangsu Jibeier Pharmaceutical Co., Ltd. Revenue for the year ending December 31, 2021 was USD 80.22 M, a -7.49% change year over year.
  • Jiangsu Jibeier Pharmaceutical Co., Ltd. Revenue for the year ending December 31, 2020 was USD 86.71 M, a 11.30% change year over year.
  • Jiangsu Jibeier Pharmaceutical Co., Ltd. Revenue for the year ending December 31, 2019 was USD 77.91 M, a 10.48% change year over year.
Key data
Date Revenue Gross Profit Operating Income EBIT
Market news
SV Wall Street
Shanghai Stock Exchange: 688566.SS

Jiangsu Jibeier Pharmaceutical Co., Ltd.

CEO Mr. Zhongyi Geng
IPO Date May 18, 2020
Location China
Headquarters High-tech Industrial Development Zone
Employees 1,445
Sector Healthcare
Industries
Pharmaceuticals Biotechnology
Description

Jiangsu Jibeier Pharmaceutical Co., Ltd., a pharmaceutical company, engages in the research, development, production, and sale of chemical preparations, proprietary Chinese medicine preparations, and bulk medicines. The company's products cover various therapeutic areas, such as improving white blood cells, enhancing immunity, treating joint diseases, anti-hypertension, anti-eye infections, treating bronchitis, protecting liver function, etc. It is also developing drugs for the treatment of depression, tumors, stomach diseases, and other diseases. The company was founded in 2001 and is based in Zhenjiang, China.

StockViz Staff

February 2, 2025

Any question? Send us an email